The AraC-resistant rat leukemic cell line RO/l-A has been shown to have a typical deoxycytidine kinase (DCK)-deficient phenotype and cannot metabolize the antileukemic drugs cytarabine (AraC) and decitabine (DAC). To investigate the relative contribution of mutations in the dck gene to the development of in vitro-induced AraC-resistance, a neomycin selectable plasmid construct harboring the wild-type dck coding region was transfected into RO/l-A. Polymerase chain reaction analysis confirmed the presence of vector DNA in the target cells (RO/l-AmK) that were stably transfected and monitored over a period of 14 weeks. Northern and Western blot analysis showed restoration of dck N ACUTE myeloid leukemia (AML), the majority of patients can achieve complete remission when treated with chemotherapeutic regimens containing l-0-D-arabinofuranosylcytosine (cytarabine; AraC) or the less commonly administered 5-aza-2'-deoxycytidine (decitabine; DAC)."3 However, after relapse of the disease a majority of the patients fail to respond to repeated treatment with either of these drugs.4 This acquired resistance to AraC and DAC is probably the main reason for eventual treatment failure in AML.5,6
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mRNA and protein expression. Initial rate measurements of DCK activity showed that K, , , values for dck were only slightly altered as a result of transfection, whereas strongly increased V, , , values were observed, resutting in a 12-fold increased phosphorylation efficiency for both dC and AraC, compared with the AraC-sensitive parental cell line R o l l from which the RO/l-A was originally derived. In vitro sensitivity to AraC-and DAC-mediated cytotoxicity was fully restored in RO/l-AMm. The data pinpoint acquired DCK deficiency caused by mutations of the dck gene as the major cause of AraC resistance in this model. 0 7 9 9 5 by The American Society of Hematology.
have described a rat model for resistant AML with an inducible and typical DCK-deficient phenotype." In this model, absence of dck-mRNA expression accompanied by a genomic rearrangement was observed in an ex vivo generated AraC-resistant cell line. Further, a point mutation was identified in dck expressed in a cell line with in vitro-induced DAC resistance. 13 To date, it is not known whether DCK deficiency is the sole cause of AraC-resistance. Flasshove et all4 have recently published the first analysis of the dck gene in patients with refractory AML who were clinically resistant to AraC treatment. They found that only 1 of 16 patients had an inactive DCK protein as a result of a pointmutation in the dck coding region. Therefore, other factors may still be necessary to create a resistant phenotype.
To address this issue, we used a leukemic rat cell line of clonal origin in which AraC resistance was induced in vitro. This cell line (RO/l-A) was shown to be cross-resistant to DAC and contained two point mutations within the dck gene, as we reported earlier." Here we describe the transfection into RO/l-A, of a plasmid construct containing wild-type dck-cDNA, to investigate the relative contribution of DCK deficiency to the acquisition of a resistant phenotype.
obtained by means of a limiting dilution assay, and thus originates from a randomly selected single RCUO ~e 1 l . l~
To induce resistance, clone R0/1 was exposed to AraC concentrations increasing from 0.1 pmoVL to 10 p m o m over a 180-day period as detailed earlier."~" All cell lines were cultured in HEPES-buffered RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (GIBCO), 4 mmol/L L-glutamine, 50 U/mL penicillin, 50 pg/mL streptomycin, and amphotericin-B. RO/l-A was cultured in the continuous presence of 10 pmol/L AraC, representing the ICso value of AraC for RCUO and R0/1 cells. Cells obtained during exponential growth phase were used for all experiments.
DCK activity assay. DCK phosphorylating activity was determined in all cell lines using an assay adapted from Cheng et As described earlier, DCK activity for the conversion of the substrates dC, AraC, was determined in crude cell extracts obtained by three cycles of freeze-thawing." The reaction mixture contained MgATP as the phosphate donor and 7 mmol/L NaF, 0.2% bovine serum albumin, and 0.2 mmol/L tetrahydrouridine (THU) to block dC-deaminating activity. Reactions were started by the addition of 20 pL of cell lysate supernatant to 150 pL of reaction mixture at 37°C. After 20, 40, and 60 minutes of reaction time 50-pL samples were spotted onto DEAE-coated paper discs (Whatman DE-81; Whatman, Maidstone, UK). Upon scintillation counting in an LKB Rackbeta liquid scintillation counter (LKB, Cambridge, UK), DCK activity was calculated by linear regression analysis of the timeresponse curves for each of the substrate concentrations and expressed in nanomoles of reaction product formed * min" * mg protein"." K,,, constants and Vmax values were calculated by nonlinear regression analysis, using the Biosoft (Cambridge, UK) scientific parameter fit software program P Fit, version 5.
Construction of pRc/CMV-DCK+. To clone the entire coding region of dck by PCR, two 25-mer oligonucleotides were synthesized. One (A65) contains six non-dck-specific nucleotides (underlined), an HindIII restriction site (italic), and the 5' end of the dck coding region with the ATG start codon (bold): 5"TGAGAAGCT-TAGCATGGCCACCCCA-3'. The other primer (B65) contains 10 non-dck-specific nucleotides (underlined), including an Xba I site (italic) and the 3' end of dck with the termination codon (bold) end:
5'-TCATGAAACACTAACAGATCTGACC-3'. Both primers were used to amplify cDNA from a healthy rat thymus sample, obtained as previously described." The amplification protocol consisted of denaturation for 5 minutes at 9 5 T , followed by 33 cycles of 95°C: 0.7 minutes, 55°C: 0.7 minutes, 72°C: 0.8 minutes. The amplification product of 809 bp was purified using a Spin-X DNA purification column (Costar, Cambridge, UK). The product was digested overnight at 37°C with 5 W100 ng HindIII and Xba I (BRL, Gaithersburg, MD). After purification, the 801-bp fragment was ligated into the HindIIIIXba I linearized pRc/CMV vector (Invitrogen, San Diego, CA). pRc/CMV is a 5.5-kb neomycin resistance selectable expression vector for eukaryotic cells. Ligation was performed at 16°C for 16 hours, using 10 U of T4 DNA ligase (Amersham, UK) and a 1:l molar vectorhnsert ratio. After transformation into the Escherichia coli strain Top10 (Invitrogen), white colonies were checked by polymerase chain reaction (PCR) for the presence of the appropriate insert, using primers for the SP6 and T7 promoters, which flank the multiple cloning site. The inserts were further analyzed for dck specificity and proper orientation within the vector using primer sets A6-B6, A2-B1, AI-SP6, and V"B2 that were used bef~re.'~.'' One clone (pRc/CMV-DCK+) was selected for large-scale plasmid isolation and purification using CsCl, density gradients following standard protocols.'* The insert was sequenced to confirm proper integration of the full-length DCK coding region.
Transfection of RO/I-A with pRc/CMV-DCK+. By means of a commercial lipofectin reagent (GIBCO BRL, Life Technologies, Gaithersburg, MD) the pRc/CMV-DCK' construct was transfected into the drug-sensitive clone R0/1 and into its AraC-resistant derivative RO/l-A, yielding cell lines RO/IDCK and RO/l-ADCK, respectively. As a control, the pRc/CMV vector was transfected into the same cell lines, yielding R0/1-and RO/I-A-. For each transfection 45 pg lipofectin reagent and 3 pg plasmid DNA were mixed in a final volume of 0.5 mL serum-free RPMI 1640 medium. Liposome-DNA complexes were allowed to form for 15 minutes at room temperature. Target cells (7.5 X 105) were washed with serum-free RPMI 1640 and resuspended in a 2.5 mL volume. The liposome-DNA mixture was added to the cell suspension and incubated in 50-mL tissue culture flasks at 37"C/5% CO2. After 5 hours, 5 mL of regular culture medium was added, and 6 mL more after another 16 hours. G418 selection was started at 75 pg/mL, 48 hours after transfection, and gradually increased to a final concentration of 800 pg/mL within 5 weeks. Every 2 days, cell growth was monitored and fresh medium added. The presence of constructs was checked by PCR on 100 ng of DNA samples from the cell lines transfected with pRc/CMV-DCK+ or pRc/CMV. Vector-specific primers SP6 and T7 and the dck-specific primers A2 and B 1 were used for amplification, in the protocol described above. Detection of dck mRNA by RT-PCR and Northern blot analysis. cDNA was reverse transcribed from 2 pg RNA, isolated by the guanidinium-isothyocyanaat protocol as described by Chomczynski et a1 with some minor modification^.'^^^^ RT-PCR on the resulting cDNA was performed using primers A6-B6 (794 bp) and A2-B1 (701 bp). Amplification of rat P-actin was used as a control."
For Northern blot analysis 20 pg of total RNA was fractionated on a 2.2 mol/L formaldehyde 1% agarose gel, transferred to Hybond-N+ nylon membranes, and subsequently hybridized at 42°C in a 50% formamide solution following routine procedures.'* RT-PCR product A2-BI (701 bp) was purified from a 0.8% low-melting-point agarose gel and used as a hybridization probe. As a positive control, rat thymus RNA was also analyzed, because of its relatively high level of dck expression."
Immunodetection of DCKprotein by Western blot analysis. Proteins were precipitated from crude cell extracts by a Nonidet P-40 sonication protocol and 30 pg of total protein was separated for 1.5 hours at 100 V on 12% polyacrylamide gels, as detailed before." Western blotting was performed as described." Briefly, the fractionated proteins were blotted to Immobilon PSQ membranes (Millipore BV, Etten-Leur, The Netherlands). The filters were blocked for 2 hours and then stained overnight by incubation with an affinitypurified rabbit-antihuman DCK polyclonal antibody (a generous gift from Dr S. Eriksson, Swedish University of Agricultural Sciences, The Biomedical Centre, Uppsala, Sweden), followed by a 2-hour incubation with '*'I-protein A (0.3 pCi/mL). As a positive control sample, a batch of purified DCK obtained from human spleen (also provided by Dr S . Eriksson) was used. Films were exposed for 48 hours before developing.
RESULTS
DCK activity in ROA and R011 -A. DCK activity for the phosphorylation of dC and AraC was measured in R0/1 and RO/l-A. In Table 1 Transfection and detection of the pRc/CMV-DCK+ construct. Previously we have presented a single-strand conformation polymorphism (SSCP) analysis of Roll-A that showed the presence of at least two pointmutations within the dck coding region." RO/I-A was transfected with a construct harboring the wild-type dck coding region, to reverse the resistant phenotype. Transfection of R0/1 and RO/I-A with either pRc/CMV or pRc/CMV-DCK' did not have a significant growth inhibitory effect. Five hours after transfection, when the serum-free RPM1 was replaced by regular culture medium, approximately 15% of cells were dead, compared with a normal viability count of 90% to 95%. Neomycin selection, started at 75 pg/mL 48 hours after transfection and gradually increased to 800 pg/mL (ie, 20-fold the ICso value for R0/1 and RO/I-A) within 5 weeks, did not cause major growth inhibitory effects. All transfected cell lines had unaltered doubling times and normal viability counts.
As shown in Fig 1, PCR performed on 1 0 0 ng of DNA
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with the T7-SP6 primer combination resulted in the amplification of an 853-bp band from RO/IDCK and RO/l-ADCK, but not from the cell lines transfected with pRc/CMV. The size of this amplicon matches that expected for the insert plus adjacent vector specific nucleotide stretches. The amplified signal was markedly stronger in RO/I-ADCK, suggesting a higher copy number in this cell line. Using dck-specific primers A2-BI on the same DNA samples, an amplicon was obtained from only those that were also positive for T7-SP6 amplification and the same difference in the intensity of the observed bands was found. Detection of dck mRNA expression by reverse transcriptase (RT)-PCR and Northern blot analysis. RT-PCR with primer sets A6-B6 (794 bp, not shown) and A2-BI (701 bp, Fig 1) yielded products from all cDNAs tested. Under these conditions amplification from ROD-A cDNA gave rise to bands that are of similar intensity as those in R0/1, suggesting a normal level of dck mRNA expression in the resistant cell line, as was found before.'' Transfection with pRc/CMV-DCK+ resulted in a strong increase of the expressed message (Fig l) , both in RO/IDCK and RO/l-ADCK.
As shown in Fig 2, Northern blot analysis revealed a high expression of dck mRNA from the construct in RO/I-AKK (lane 3) and a markedly lower expression in RO/lDCK (lane 1). mRNA expressed from the plasmid was expected to have a length of approximately 1.15 kb, but was always observed as a smear between 0.4 and 1.4 kb. A titration of RO/I-ADCK RNA resulted in the detection of a more defined band of 51.2 kb, readily detectable in 2.5 pg of total RNA (not shown). At short exposure times of 2 days (Fig 2A) expression of the normal-length dck mRNA (4.1 kb") could only be detected in thymus cells, which were used as a positive control, but not in any of the other cell lines. At long exposure of 18 days (Fig 2B) , the 4.1-kb transcript was detected in all cell lines except RO/I-A. Interestingly, this lack of expression of normal-length dck mRNA appears to be restored in RO/I-ADCK cells (lane 3). Transfection with pRc/ CMV alone did not affect normal expression levels (lanes 2 1 2 3 4 M 5 6 t T7-SP6 (Fig 2C) . Detection of DCK protein expression by Western blot analysis. To establish whether the increased dck mRNA expression observed by Northern blot analysis leads to a higher production of DCK protein, Western blot analysis was performed, using a rabbit-antihuman DCK polyclonal antibody. A human protein pool, enriched for DCK, was used as a control (Fig 3, lane C Restoration of DCK activify. To investigate whether the observed expression of DCK protein in the transfected cells led to a restoration of DCK enzymatic activity, the activity of the enzyme toward dC and AraC was measured ( Table  1) . The assay used to measure initial rate DCK conversion was linear for time and protein. Transfection of R0/1 resulted in a 1 .&fold increase of the V , value for dC in RO/ lDCK but did not affect the K,,, value significantly (1.14-fold). Identical results were obtained in RO/IDCK with respect to AraC conversion, with a K, value similar to R0/1 (235.2 c 1 2 3 4 In contrast, RO/l-ADCK has a strongly increased affinity for dC (43-fold) compared to RO/1-A, with K, values of the same magnitude as those observed for its parental sensitive clone R0/1 (21.6 pmoVL and 15 pmoVL, respectively), as well as a 4.7-fold increased V, , value. The conversion rate in RO/l-ADCK, is 18-fold that of R0/1. For AraC, the K,,, is increased 2. 1-fold and the V, , 26-fold compared with R0/1. Transfection with the pRc/CMV vector alone had no significant effect on DCK kinetic constants in the resulting RO/1-and RO/1-A-cell lines (not shown).
The antiproliferative effect of AraC on R0/1, RO/l-A, and RO/l-ADCK was studied by the addition of varying concentrations of the drug to the cell culture medium. ICso values were calculated from the resulting growth inhibition curves shown in Fig 4, after 48 hours of continuous exposure. In comparison with R0/1, RO/l-A has become more than 9,000-fold resistant to AraC, with an ICso of > l 0 mmol/L. As a result of the transfection of pRc/CMV-DCK' into RO/ l-A, the sensitivity toward AraC was fully restored. The IC,, value of 0.85 pmoVL in ROD-ADCK is comparable with that of the original R0/1 (1.1 pmol/L).
DISCUSSION
Resistance to the antimetabolite AraC is known to be marked by DCK deficiency mediated by mutations in the deoxycytidine kinase gene, as we and others have s h o~n .~~* '~ However, it is not clear whether mutations in the dck locus are the sole cause of DCK protein deficiency and or whether factors other than functional DCK inactivity may still be inv01ved.I~ In order to investigate the relative role of dck mutations in the development of a resistant phenotype, we have transfected a plasmid construct containing the wildtype dck coding region into an AraC-resistant cell line of clonal origin (RO/1-A). This approach has resulted in the complete restoration sensitivity to AraC in the formerly resistant target cells.
RO/1-A was generated in vitro by exposure of R011 (in turn derived from RCL/O by limiting dilution) to gradually increasing concentrations of AraC." RO/l-A has a DCKdeficient phenotype as can be seen from the kinetic constants presented in Table 1 and has similar characteristics as an ex vivo generated AraC-resistant cell line we described earlier." As was argued before, the residual metabolization of dC that is found may be the result of the presence of another nucleoside phosphokinase in our crude cellular extracts, most likely the mitochondrial thymidine kinase 2, that is known to phosphorylate dC, but not AraC?4,25 Earlier we have analyzed the dck gene in RO/1-A and found evidence for the presence of two pointmutations by SSCP analysis.15
After transfection, evidence for the presence of the pRcl CMV-DCK+ construct in RO/lDCK and RO/1-ADCK was obtained by PCR on genomic DNA samples, showing the expected 853-bp product for primer combination T7-SP6 in these cell lines, but not in R0/1-and RO/l-A-. Although this assay does not discriminate between amplification from construct-DNA integrated into the host genome or amplification from episomally present pRc/CMV-DCK+, both cell lines were stably transfected over a period of 14 weeks to date.
By RT-PCR, high expression of dck mRNA was seen in both transfected lines, with a somewhat stronger signal in the RO/l-ADCK. A much higher difference in expression and activity was observed between RO/1-ADCK and RO/lDCK by Northern, Western, and DCK-activity analysis. However, the PCR method used was not expected to provide reliable quantitative data.
Northern blot analysis shows a very high expression of dck-mRNA of vector origin in RO/1-ADCK and only a marginal expression in RO/lDCK. Bands representing normallength dck-mRNA of 4.1 kb could only be detected after extremely long exposure times of up to 18 days, except in rat thymus that has a high constitutive expression of dck &A."
Interestingly, in the RO/l-ADCK a weak expression of normal-length dck mRNA (4.1 kb) was observed that was not expressed in RO/1-A before transfection. This could suggest the involvement of transcriptional regulation mecha-nisms in RO/l-A as a second factor contributing to the AraCresistant phenotype, in addition to the mutational events affecting the dck gene.
Western blot analysis showed that transfection resulted in a very high expression of DCK protein in the RO/l-ADCK that previously did not express any detectable amounts. In the RO/lDCK no elevation of DCK protein levels when compared with R0/1 was observed, confirming the results of Northern blot analysis. The rabbit-antihuman DCK polyclonal antibody used for immunoblotting recognized rat DCK just as well as it did human DCK. The 30.5-kD subunit of the DCK protein was readily detected in RO/1. This is in agreement with the high homology of the rat amino acid sequence (91.9%) that we reported previously." The same antibody has also been used for the detection of mouse DCK, which is 94.6% homologous to the human Initial rate measurements of DCK activity show a mild increase in RO/lDCK (1.6-fold) of the Vm/K, ratio (for dC), demonstrating a marginal effect of transfecting wild-type dck into this wild-type clone. It is not clear why the transfection of dck into R0/1 has apparently been less successful. Despite the presence of substantial amounts of pRc/CMV-DCK', as assessed by PCR, and the expression of elevated levels of dck transcripts, no substantial elevation of mRNA, protein, or DCK-activity levels were found in RO/lDCK. Possibly, the normal regulation of DCK expression in these cells also controls the expression of DCK from the vector and strives to maintain normal levels of functional DCK.
The increase in DCK phosphorylating activity was substantial in RO/l-ADCK and could not be adequately measured without diluting the enzyme samples. The V-&, ratios for dC conversion in RO/l-ADCK increased 12.5-fold and 204-fold compared with the parental R0/1 and the resistant RO/ l-A, respectively, indicating a restoration of DCK activity to levels higher than in wild-type cells. AraC phosphorylation in R O / I -A~~~ was restored at a conversion rate level 26.4-fold higher than in the parent R0/1. K, values for dC and AraC were not significantly altered in RO/IDCK and RO/ l-ADCK, compared with RO/1, indicating that the enzyme translated from the construct and the natural DCK protein have a similar affinity for both substrates. The K, value for dC decreased from 921 pmol/L in RO/1-A to 17. l pmol/L in RO/l-ADCK, confirming that the construct-derived protein has a normal affinity for dC. In RO/I-ADCK an unexpected but significant concomitant 2.1-fold increase of the affinity constant for AraC was observed, whereas it was of normal magnitude in RO/lDCK.
In conclusion, we have shown that transfection of wildtype dck cDNA into an AraC-resistant cell line results in the complete restoration of sensitivity to AraC cytotoxicity. The results indicate that DCK deficiency, mediated by mutations in the dck gene, is the crucial factor in the development of AraC resistance in this cell line.
